Neurocrine Biosciences, Inc. (NBIX)
128.42
-3.02
(-2.30%)
USD |
NASDAQ |
Apr 16, 16:00
128.42
0.00 (0.00%)
After-Hours: 20:00
Neurocrine Biosciences Research and Development Expense (Quarterly) : 258.20M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Soleno Therapeutics, Inc. | 9.558M |
| Glaukos Corp. | 43.65M |
| Edgewise Therapeutics, Inc. | 43.07M |
| Nuvalent, Inc. | 67.80M |
| Biogen, Inc. | 434.00M |